BioCryst: Difference between revisions
Jump to navigation
Jump to search
Patriarca12 (talk | contribs) No edit summary |
m (BioCryst Pharmaceuticals Inc. moved to BioCryst: command decision to use the common name here.) |
(No difference)
|
Revision as of 10:44, 21 September 2006
BioCryst Pharmaceuticals Inc. (NASDAQ:BDRX) is a pharmaceutical company based at 2190 Parkway Lake Drive in Birmingham. The company, which began in 1986, manufactures various types of perscription drugs. Its two most well-known products include a treatment of T-cell mediated disorders called BCX-1777 and another treatment for T-cell mediated autoimmune diseases called BCX-4208.
The CEO and Chairman of the Board is Dr. Charles E. Bugg, who was one of the companies co-founders in 1986. Set to retire in 2007, under Brugg's leadership, the company went public in 1994 seeing moderate profits.
References
- BioCryst Pharmaceuticals Inc. corporate spotling at NASDAQ. - Accessed September 21, 2006
- Hubbard, Russell. (September 21, 2006) "BioCryst says CEO will retire in 2007." Birmingham News.
External links
- BioCryst Pharmaceuticals Inc. website